…
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -1.48M | -1.61M | -1.82M | -3.42M | -4.43M |
| Net income | 0.70M | -1.61M | -1.82M | -3.42M | -4.43M |
| Selling general administrative | 2.09M | 1.02M | 0.48M | 1.35M | 2.69M |
| Gross profit | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Reconciled depreciation | - | - | 0.00M | 0.00M | 0.00M |
| Ebit | -3.67M | - | - | -2.45M | -2.38M |
| Ebitda | -4.40M | -1.10M | -0.83M | -2.45M | -2.38M |
| Depreciation and amortization | -0.73M | - | - | 0.00M | 0.00M |
| Operating income | -3.67M | -1.10M | -0.83M | -2.45M | -2.79M |
| Other operating expenses | 3.67M | 1.10M | 0.83M | 2.45M | 2.79M |
| Interest expense | 2.18M | 0.81M | 1.00M | 0.98M | 1.23M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.73M | -0.81M | -1.00M | -0.98M | -1.23M |
| Income tax expense | -2.18M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 3.67M | 1.10M | 0.83M | 2.45M | 2.79M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total other income expense net | 2.18M | -0.51M | -1.00M | -0.98M | -0.41M |
| Net income from continuing ops | -1.48M | -1.61M | -1.82M | -3.42M | -4.43M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3.74M | 8.50M | 6.68M | 0.00M | 0.03M |
| Other current assets | 0.71M | - | - | - | 0.01M |
| Total liab | 0.83M | 2.55M | 0.10M | 13.69M | 11.90M |
| Total stockholder equity | 2.91M | 5.95M | 6.58M | -13.69M | -11.87M |
| Other current liab | 0.47M | 2.55M | - | 1.50M | 0.54M |
| Common stock | 0.00M | 0.02M | 0.01M | 0.03M | 0.03M |
| Capital stock | 0.00M | 0.02M | 0.01M | 0.03M | 0.03M |
| Retained earnings | -80.91M | -71.96M | -70.48M | -68.86M | -67.04M |
| Other assets | - | 0.00M | - | - | - |
| Cash | 3.03M | 7.54M | 6.68M | 0.00M | 0.02M |
| Total current liabilities | 0.83M | 2.55M | 0.10M | 13.69M | 0.58M |
| Net debt | -3.03M | -7.54M | -6.68M | 11.72M | 11.30M |
| Short term debt | - | - | - | 11.72M | - |
| Short long term debt | - | - | - | 11.72M | - |
| Short long term debt total | - | - | - | 11.72M | 11.32M |
| Other stockholder equity | 83.81M | 77.89M | 77.04M | 55.14M | 55.14M |
| Total current assets | 3.74M | 8.50M | 6.68M | 0.00M | 0.03M |
| Net receivables | 0.33M | - | - | - | - |
| Long term debt | - | - | - | - | 11.32M |
| Inventory | -0.33M | - | - | - | - |
| Accounts payable | 0.36M | 0.00M | 0.10M | 0.47M | 0.04M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total cash from financing activities | 4.43M | 7.90M | 0.40M | 2.32M | 4.37M |
| Net income | -1.48M | -1.61M | -1.82M | -3.42M | -4.43M |
| Change in cash | 0.86M | 6.68M | -0.02M | -0.93M | 0.27M |
| Begin period cash flow | 6.68M | 0.00M | 0.02M | 0.96M | 0.69M |
| End period cash flow | 7.54M | 6.68M | 0.00M | 0.02M | 0.96M |
| Total cash from operating activities | -3.57M | -1.23M | -0.43M | -3.25M | -4.10M |
| Issuance of capital stock | 4.43M | 6.86M | - | 0.00M | 4.37M |
| Depreciation | - | - | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | 4.43M | 1.06M | 0.40M | 2.32M | 0.60M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.17M | -0.32M | 0.40M | 0.14M | 0.15M |
| Stock based compensation | 0.27M | 0.21M | 0.06M | 0.05M | 0.52M |
| Other non cash items | -2.18M | 0.50M | 0.94M | 0.26M | 0.38M |
| Free cash flow | -3.57M | -1.23M | -0.43M | -3.25M | -4.10M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
2 Burlington Woods Drive, Burlington, MA, United States, 01803
781 552 4452
2
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey Frelick | CEO & President | 1966 |
| Ms. Deina H. Walsh | Chief Financial Officer | 1964 |
| Dr. Shun'ichi Kuroda | Co-Founder & Member of Scientific Advisory Board | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.